Dasatinib, 98%, a dual Bcr-Abl and Src family tyrosine kinase inhibitor with IC50s of 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit and c-KitD816V, respectively

Name: Dasatinib, 98%, a dual Bcr-Abl and Src family tyrosine kinase inhibitor with IC50s of 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit and c-KitD816V, respectively | 302962-49-8
Brand: J&K Chemical
SKU: JK923898_500_MG
Price: 299.0 USD
Availability: OutOfStock

Cat. No JK923898_500_MG

Vendor: J&K Chemical

Product Information

Product Name

Dasatinib, 98%, a dual Bcr-Abl and Src family tyrosine kinase inhibitor with IC50s of 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit and c-KitD816V, respectively

Brand Name

J&K

Product Number

923898

CAS

302962-49-8

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

3062316

IUPAC Name

N-(2-chloro-6-methylphenyl)-2-6-4-(2-hydroxyethyl)piperazin-1-yl-2-methylpyrimidin-4-ylamino-1,3-thiazole-5-carboxamide

InChI Key

ZBNZXTGUTAYRHI-UHFFFAOYSA-N

SMILES

CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO

Safety Information

Storage Condition

Freezer -20℃

References

Quantum chemical treatment, electronic energy in various solvents, spectroscopic, molecular docking and dynamic simulation studies of 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide: A core of anticancer drug

Publication Name: Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy

Publication Date: 2025-02-05

DOI: 10.1016/j.saa.2024.125263

Enhancing oral bioavailability of dasatinib via supersaturable SNEDDS: Investigation of precipitation inhibition and IVIVC through in-vitro lipolysis-permeation model

Publication Name: International Journal of Pharmaceutics

Publication Date: 2025-01-05

DOI: 10.1016/j.ijpharm.2024.125007

Senolytics cocktail dasatinib and quercetin alleviate chondrocyte senescence and facet joint osteoarthritis in mice

Publication Name: The spine journal : official journal of the North American Spine Society

Publication Date: 2025-01

DOI: 10.1016/j.spinee.2024.09.017

Method to Assess Immunosenescent CD8+ T Cells in Respiratory Viral Infections

Publication Name: Methods in molecular biology (Clifton, N.J.)

Publication Date: 2025

DOI: 10.1007/978-1-0716-4128-6_4

Growth retardation and adult height in pediatric patients with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

Publication Name: Leukemia

Publication Date: 2024-12-12

DOI: 10.1038/s41375-024-02488-0

Dasatinib, 98%, a dual Bcr-Abl and Src family tyrosine kinase inhibitor with IC50s of 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit and c-KitD816V, respectively

Product Information

General Information

Safety Information

References

Quantum chemical treatment, electronic energy in various solvents, spectroscopic, molecular docking and dynamic simulation studies of 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide: A core of anticancer drug

Enhancing oral bioavailability of dasatinib via supersaturable SNEDDS: Investigation of precipitation inhibition and IVIVC through in-vitro lipolysis-permeation model

Senolytics cocktail dasatinib and quercetin alleviate chondrocyte senescence and facet joint osteoarthritis in mice

Method to Assess Immunosenescent CD8+ T Cells in Respiratory Viral Infections

Growth retardation and adult height in pediatric patients with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors